tetano
Editor, Senior Moderator
Nature
. 2020 Sep 30.
doi: 10.1038/s41586-020-2814-7. Online ahead of print.
COVID-19 vaccine BNT162b1 elicits human antibody and T [SUB]H[/SUB] 1 T-cell responses
Ugur Sahin[SUP] 1 2 [/SUP], Alexander Muik[SUP] 3 [/SUP], Evelyna Derhovanessian[SUP] 3 [/SUP], Isabel Vogler[SUP] 3 [/SUP], Lena M Kranz[SUP] 3 [/SUP], Mathias Vormehr[SUP] 3 [/SUP], Alina Baum[SUP] 4 [/SUP], Kristen Pascal[SUP] 4 [/SUP], Jasmin Quandt[SUP] 3 [/SUP], Daniel Maurus[SUP] 3 [/SUP], Sebastian Brachtendorf[SUP] 3 [/SUP], Verena L?rks[SUP] 3 [/SUP], Julian Sikorski[SUP] 3 [/SUP], Rolf Hilker[SUP] 3 [/SUP], Dirk Becker[SUP] 3 [/SUP], Ann-Kathrin Eller[SUP] 3 [/SUP], Jan Gr?tzner[SUP] 3 [/SUP], Carsten Boesler[SUP] 3 [/SUP], Corinna Rosenbaum[SUP] 3 [/SUP], Marie-Cristine K?hnle[SUP] 3 [/SUP], Ulrich Luxemburger[SUP] 3 [/SUP], Alexandra Kemmer-Br?ck[SUP] 3 [/SUP], David Langer[SUP] 3 [/SUP], Martin Bexon[SUP] 5 [/SUP], Stefanie Bolte[SUP] 3 [/SUP], Katalin Karik?[SUP] 3 [/SUP], Tania Palanche[SUP] 3 [/SUP], Boris Fischer[SUP] 3 [/SUP], Armin Schultz[SUP] 6 [/SUP], Pei-Yong Shi[SUP] 7 [/SUP], Camila Fontes-Garfias[SUP] 7 [/SUP], John L Perez[SUP] 8 [/SUP], Kena A Swanson[SUP] 8 [/SUP], Jakob Loschko[SUP] 8 [/SUP], Ingrid L Scully[SUP] 8 [/SUP], Mark Cutler[SUP] 8 [/SUP], Warren Kalina[SUP] 8 [/SUP], Christos A Kyratsous[SUP] 4 [/SUP], David Cooper[SUP] 8 [/SUP], Philip R Dormitzer[SUP] 8 [/SUP], Kathrin U Jansen[SUP] 8 [/SUP], ?zlem T?reci[SUP] 3 [/SUP]
Affiliations
Abstract
An effective vaccine is needed to halt the spread of the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) pandemic. Recently, we reported safety, tolerability and antibody response data from an ongoing placebo-controlled, observer-blinded phase 1/2 coronavirus disease 2019 (COVID-19) vaccine trial with BNT162b1, a lipid nanoparticle (LNP) formulated nucleoside-modified messenger RNA (mRNA) encoding the receptor binding domain (RBD) of the SARS-CoV-2 spike protein[SUP]1[/SUP]. Here we present antibody and T-cell responses after BNT162b1 vaccination from a second, non-randomized open-label phase 1/2 trial in healthy adults, 18-55 years of age. Two doses of 1 to 50 ?g of BNT162b1 elicited robust CD4[SUP]+[/SUP] and CD8[SUP]+[/SUP] T-cell responses and strong antibody responses, with RBD-binding IgG concentrations clearly above those in a COVID-19 human convalescent sample (HCS) panel. Day 43 SARS-CoV-2 serum neutralising geometric mean titers were 0.7-fold (1 ?g) to 3.5-fold (50 ?g) those of the HCS panel. Immune sera broadly neutralised pseudoviruses with diverse SARS-CoV-2 spike variants. Most participants had T helper type 1 (T[SUB]H[/SUB]1) skewed T cell immune responses with RBD-specific CD8[SUP]+[/SUP] and CD4[SUP]+[/SUP] T-cell expansion. Interferon (IFN)γ was produced by a high fraction of RBD-specific CD8[SUP]+[/SUP] and CD4[SUP]+[/SUP] T cells. The robust RBD-specific antibody, T-cell and favourable cytokine responses induced by the BNT162b1 mRNA vaccine suggest multiple beneficial mechanisms with potential to protect against COVID-19.
. 2020 Sep 30.
doi: 10.1038/s41586-020-2814-7. Online ahead of print.
COVID-19 vaccine BNT162b1 elicits human antibody and T [SUB]H[/SUB] 1 T-cell responses
Ugur Sahin[SUP] 1 2 [/SUP], Alexander Muik[SUP] 3 [/SUP], Evelyna Derhovanessian[SUP] 3 [/SUP], Isabel Vogler[SUP] 3 [/SUP], Lena M Kranz[SUP] 3 [/SUP], Mathias Vormehr[SUP] 3 [/SUP], Alina Baum[SUP] 4 [/SUP], Kristen Pascal[SUP] 4 [/SUP], Jasmin Quandt[SUP] 3 [/SUP], Daniel Maurus[SUP] 3 [/SUP], Sebastian Brachtendorf[SUP] 3 [/SUP], Verena L?rks[SUP] 3 [/SUP], Julian Sikorski[SUP] 3 [/SUP], Rolf Hilker[SUP] 3 [/SUP], Dirk Becker[SUP] 3 [/SUP], Ann-Kathrin Eller[SUP] 3 [/SUP], Jan Gr?tzner[SUP] 3 [/SUP], Carsten Boesler[SUP] 3 [/SUP], Corinna Rosenbaum[SUP] 3 [/SUP], Marie-Cristine K?hnle[SUP] 3 [/SUP], Ulrich Luxemburger[SUP] 3 [/SUP], Alexandra Kemmer-Br?ck[SUP] 3 [/SUP], David Langer[SUP] 3 [/SUP], Martin Bexon[SUP] 5 [/SUP], Stefanie Bolte[SUP] 3 [/SUP], Katalin Karik?[SUP] 3 [/SUP], Tania Palanche[SUP] 3 [/SUP], Boris Fischer[SUP] 3 [/SUP], Armin Schultz[SUP] 6 [/SUP], Pei-Yong Shi[SUP] 7 [/SUP], Camila Fontes-Garfias[SUP] 7 [/SUP], John L Perez[SUP] 8 [/SUP], Kena A Swanson[SUP] 8 [/SUP], Jakob Loschko[SUP] 8 [/SUP], Ingrid L Scully[SUP] 8 [/SUP], Mark Cutler[SUP] 8 [/SUP], Warren Kalina[SUP] 8 [/SUP], Christos A Kyratsous[SUP] 4 [/SUP], David Cooper[SUP] 8 [/SUP], Philip R Dormitzer[SUP] 8 [/SUP], Kathrin U Jansen[SUP] 8 [/SUP], ?zlem T?reci[SUP] 3 [/SUP]
Affiliations
- PMID: 32998157
- DOI: 10.1038/s41586-020-2814-7
Abstract
An effective vaccine is needed to halt the spread of the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) pandemic. Recently, we reported safety, tolerability and antibody response data from an ongoing placebo-controlled, observer-blinded phase 1/2 coronavirus disease 2019 (COVID-19) vaccine trial with BNT162b1, a lipid nanoparticle (LNP) formulated nucleoside-modified messenger RNA (mRNA) encoding the receptor binding domain (RBD) of the SARS-CoV-2 spike protein[SUP]1[/SUP]. Here we present antibody and T-cell responses after BNT162b1 vaccination from a second, non-randomized open-label phase 1/2 trial in healthy adults, 18-55 years of age. Two doses of 1 to 50 ?g of BNT162b1 elicited robust CD4[SUP]+[/SUP] and CD8[SUP]+[/SUP] T-cell responses and strong antibody responses, with RBD-binding IgG concentrations clearly above those in a COVID-19 human convalescent sample (HCS) panel. Day 43 SARS-CoV-2 serum neutralising geometric mean titers were 0.7-fold (1 ?g) to 3.5-fold (50 ?g) those of the HCS panel. Immune sera broadly neutralised pseudoviruses with diverse SARS-CoV-2 spike variants. Most participants had T helper type 1 (T[SUB]H[/SUB]1) skewed T cell immune responses with RBD-specific CD8[SUP]+[/SUP] and CD4[SUP]+[/SUP] T-cell expansion. Interferon (IFN)γ was produced by a high fraction of RBD-specific CD8[SUP]+[/SUP] and CD4[SUP]+[/SUP] T cells. The robust RBD-specific antibody, T-cell and favourable cytokine responses induced by the BNT162b1 mRNA vaccine suggest multiple beneficial mechanisms with potential to protect against COVID-19.